PRG Korea

PRG Science & Pharma is a South Korean biotechnology company dedicated to developing innovative treatments for rare genetic disorders and age-related diseases. The company's core research focuses on protein-protein interaction (PPI) inhibitors, specifically targeting the progerin protein to treat Hutchinson-Gilford Progeria Syndrome (HGPS). Their lead asset, PRG-N-001, has received Orphan Drug Designation from the U.S. FDA and is currently in clinical development. Beyond progeria, PRG Science & Pharma is leveraging its expertise to develop a pipeline of small molecules for Alzheimer's disease, ALS, and type 2 diabetes. The company aims to address significant unmet medical needs in the field of healthy aging and rare disease management.